Immunitybio Inc (IBRX) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The study “Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer” tests a new drug mix before and after surgery in tough pancreatic cancer. It aims to check safety and early signs of benefit, which could be important if results later support a larger program and potential new uses for ImmunityBio, Inc. products.
The trial uses a chemo‑immunotherapy combo built around nogapendekin alfa inbakicept, also known as N‑803 or ANKTIVA. It adds sotevtamab, zabadinostat, and standard chemo drugs gemcitabine and nab‑paclitaxel, with the goal of shrinking tumors before surgery and then keeping cancer from coming back after surgery.
This is an interventional Phase 1 trial with one treatment group and no randomization, so all patients get the same regimen. It is open‑label with no masking, and the main goal is treatment focused, meaning the study is meant to see how patients tolerate the combo and whether it shows enough promise to justify larger, more definitive studies.
The study is sponsored by ImmunityBio, Inc. and is listed as “Not yet recruiting,” so enrollment has not started. The record shows an initial submission date of November 20, 2025 and the latest update on April 28, 2026, signaling that the design has been refreshed, but key timing for primary and final completion has not yet been posted for investors.
For markets, the update highlights ImmunityBio’s push to expand N‑803 into high‑need solid tumors like pancreatic cancer, which has few options and strong pricing power if a therapy works. While early‑stage and high risk, progress here could boost long‑term sentiment for IBRX versus larger oncology peers and combo competitors, though near‑term revenue impact remains distant.
The study remains in the startup phase with updated details now live, and investors can follow future changes and milestones on the ClinicalTrials.gov portal under identifier NCT07488884.
To learn more about IBRX’s potential, visit the Immunitybio Inc drug pipeline page.